June 2007 -

LIFE-SAVING DIABETES INVENTION FAST-TRACKED BY GOVERNMENT
Sydney-based AiMedics has won a major Federal Government grant to fast-track the development of a unique non-invasive device that alerts insulin-dependent diabetics of life-threatening hypoglycaemia (low blood-sugar levels).

AiMedics Chairman, Martin Greenberg, said today that the Federal Department of Industry had granted the company up to $2.755 Million to accelerate the commercial development of its HypoMon® product to assist the growing number of insulin-dependent diabetics in Australia and around the world.

Hypoglycaemia can lead to coma, seizures or death, unless it is detected early enough and counteracted with a ‘sugar’-based product such as orange juice or intravenous glucose.

AiMedics CEO, Victor Skladnev, said the Commonwealth funding would complement the significant investment in HypoMon® already committed by GBS Venture Partners.

“We are very pleased with the ‘commercial-ready’ grant which will help us to get our valuable and potentially life-saving device on the market and available to those suffering from insulin-dependent diabetes,” Mr Skladnev said.

Australian Industry Minister, Ian Macfarlane, said HypoMon® was a great example of how Australian innovation is helping to deliver real health benefits to people with chronic illnesses.

"Diabetes is one of Australia's fastest growing chronic diseases and improving the detection of low blood sugar levels will greatly enhance the health outcome of patients," Mr Macfarlane said.

"The Australian government's Commercial Ready grant will ensure the potentially life-saving device is commercialised and in the hands of those who need it as soon as possible."

May 2007 -
Expansion of staff including the appointment of a R&D Engineer(Francesco La Tella), Mathematician(Bernadette Le Mesurier) and a Senior Devices Scientist (Dr. Stan Tarnavskii).

April 2007 -
AiMedics commences the overnight Stage II (Glucose - freefall) clinical studies of the HypoMon® for Type1 diabetic children at the Princess Margaret Hospital for children (PMH) in Perth.

November 2006 -
Expansion of staff including the appointment of a CEO (Victor Skladnev), Senior Electronics Engineer (Theo Masselos) and a Software Engineer (Raymond Sinn).

November 2006 -
The conclusion of the HypoMon® children pre-clinical studies were presented at the 6th Annual Diabetes Technology Meeting, Atlanta 2006.

October 2006 -
AiMedics commences the overnight Stage I (Glucose - clamp) clinical studies of the HypoMon® for Type1 diabetic children at the Princess Margaret Hospital for children (PMH) in Perth.

September 2006 -
AiMedics has securred venture capital funding of $4.5 million through GBS Venture Partners and the initial AiMedics investors. GBS (GBS Ventures) is one of Australia’s leading life sciences venture capital groups and has had considerable success in building companies based on Australian technology. The new funding from GBS will be used to further the development of HypoMon®.

June 2006 -
The results of the HypoMon® paediatric pre-clinical studies were presented at the 66th Annual American Diabetes Association (ADA) Conference, Washington DC 2006.

January 2006 -
AiMedics concludes the pre-clinical studies of the HypoMon® both at the Prince of Wales Hospital (Adult population) and at the Princess Margaret Hospital (Children population).

November 2005 -
The results of the HypoMon® children pre-clinical studies were presented at the 5th Annual Diabetes Technology Meeting, San Francisco 2005.

September 2005 -
Frontline Systems (Frontline) provides Sun Microsystems™ multi-processor workstations for computational algorithm development.

June 2005 -
The results of the HypoMon® adult pre-clinical studies were presented at the 65th Annual American Diabetes Association (ADA) Conference, San Diego 2005.

March 2005 -
AiMedics commences clinical studies of the HypoMon® for Type1 diabetic children at the Princess Margaret Hospital for children (PMH) in Perth.

February 2005 -
AiMedics is formally granted the HypoMon® New Zealand patent. Pat No. 527818.

page: Next